Lakefront Biotherapeutics American Depositary Shares
LKFT
79 hedge funds and large institutions have $698M invested in Lakefront Biotherapeutics American Depositary Shares in 2018 Q2 according to their latest regulatory filings, with 12 funds opening new positions, 27 increasing their positions, 25 reducing their positions, and 13 closing their positions.
8% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 25
7% less call options, than puts
Call options by funds: $3.8M | Put options by funds: $4.11M
8% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 13
2.75% less ownership
Funds ownership: 17.5% → 14.75% (-2.8%)
4% less funds holding
Funds holding: 82 → 79 (-3)
22% less capital invested
Capital invested by funds: $894M → $698M (-$196M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$11.8M |
| 2 |
ACM
Atika Capital Management
New York
|
+$3.98M |
| 3 |
DM
Deerfield Management
New York
|
+$3.4M |
| 4 |
Morgan Stanley
New York
|
+$1.48M |
| 5 |
ERSOT
Employees Retirement System of Texas
Austin,
Texas
|
+$1.46M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$101M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$30.8M |
| 3 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$5.54M |
| 4 |
PA
Perceptive Advisors
New York
|
-$5.38M |
| 5 |
Renaissance Technologies
New York
|
-$5.05M |
LKFT Hedge Fund Activity: Q2 2018 in Review
79 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in Lakefront Biotherapeutics American Depositary Shares (LKFT) for Q2 2018, worth a combined $698M — down 22% from $894M a quarter earlier.
Sellers outnumbered buyers: 13 funds closed out of LKFT and 12 opened new positions — a net loss of 1 holder — while 25 trimmed existing stakes and 27 added.
The largest buyer was Federated Hermes, adding an estimated $11.8M. The largest seller was Fidelity Investments, cutting an estimated $101M.
- 79 institutional investors held Lakefront Biotherapeutics American Depositary Shares (LKFT) as of Q2 2018, down from 82 in Q1 2018.
- Funds reported $698M of Lakefront Biotherapeutics American Depositary Shares stock for Q2 2018, down 22% quarter-over-quarter.
- 12 funds opened new Lakefront Biotherapeutics American Depositary Shares positions in Q2 2018 and 13 closed out, a net change of -1 holder.
- The largest Lakefront Biotherapeutics American Depositary Shares buyer in Q2 2018 was Federated Hermes, an estimated $11.8M added.
- The largest Lakefront Biotherapeutics American Depositary Shares seller in Q2 2018 was Fidelity Investments, an estimated $101M sold.
Based on aggregated 13F filings for Q2 2018.